February 26, 2020 Go or no go? Ozanimod and Fintepla await FDA verdicts Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's Fintepla will be scrutinised.
